Reduced JAK Inhibitor Dosing May Not Compromise RA Outcomes

Published Date: 26 May 2026

In patients with rheumatoid arthritis and preserved kidney function, reduced initial doses of JAK inhibitors show 2-year treatment persistence and disease control similar to those with standard doses.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Approves Treosulfan as Part of AML/MDS Conditioning Regimen

2.

'Ticking Time Bomb'; Jimmy Carter's Lasting Impact on Cancer; Breast Cancer-CVD Link

3.

Millions of men could benefit from faster scan to diagnose prostate cancer

4.

Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma

5.

Key mechanism behind prostate cancer drug resistance reveals potential new treatment strategy


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot